



(51) International Patent Classification:

C07K 5/06 (2006.01) **A61K 38/06** (2006.01)
C07K 5/08 (2006.01) **A01N 43/00** (2006.01)
A61P 37/08 (2006.01)

(21) International Application Number:

PCT/GB2011/000079

(22) International Filing Date:

21 January 2011 (21.01.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1001070.0 22 January 2010 (22.01.2010) GB

(71) Applicants (for all designated States except US): **ST GEORGE'S HOSPITAL MEDICAL SCHOOL** [GB/GB]; Cranmer Terrace, Tooting, London SW17 0RE (GB). **THE UNIVERSITY OF MANCHESTER** [GB/GB]; Oxford Road, Manchester M13 9PL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROBINSON, Clive** [GB/GB]; St George's University of London, Cranmer Terrace, Tooting, London SW17 0RE (GB). **ZHANG, Ji-hui** [CN/GB]; St George's University of London, Cranmer Terrace, Tooting, London SW17 0RE (GB). **GARROD, David, Ronald** [GB/GB]; Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT (GB). **PERRIOR, Trevor, Robert** [GB/GB]; Domainex Ltd, 324 Cambridge Science Park, Cambridge CB4 0WG (GB). **NEWTON, Gary, Karl** [GB/GB]; Domainex Ltd, 324 Cambridge Science Park, Cambridge CB4 0WG (GB). **JENKINS, Kerry** [GB/GB]; Domainex Ltd, 324 Cambridge Science Park, Cambridge CB4 0WG (GB). **BEEVERS, Rebekah, Elisabeth** [GB/GB]; Domainex Ltd, 324 Cambridge Science Park, Cambridge CB4 0WG (GB). **KIMBERLEY, Meriel, Ruth** [GB/GB]; Domainex Ltd, 324 Cambridge

Science Park, Cambridge CB4 0WG (GB). **STEWART, Mark, Richard** [GB/GB]; Domainex Ltd, 324 Cambridge Science Park, Cambridge CB4 0WG (GB).

(74) Agents: **WYTENBURG, Wilhelmus, J** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London EC2V 8AS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

26 April 2012

(54) Title: PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN



(57) Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as "PVA compounds"), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.